MedTrace Logo

An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

NCT02759042 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2018-03-13

No results posted yet for this study

Summary

The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140\_CD02.

Conditions

Interventions

DRUG

PRO 140

PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Sponsors & Collaborators

  • Amarex Clinical Research

    collaborator OTHER

  • CytoDyn, Inc.

    lead INDUSTRY

Principal Investigators

  • Edwin DeJesus, MD, FIDSA · Orlando Immunology Center

Eligibility

Min Age
55 Years
Max Age
56 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02759042 on ClinicalTrials.gov